BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) Relative Strength Index (RSI) is 63.37, with weekly volatility at 8.99% and ATR at 0.89. The BCRX stock’s 52-week price range has touched low of $1.58 and a $12.90 high. Intraday shares traded counted 8.32 million, which was 0.33% higher than its 30-day average trading volume of 8.35M. Its shares traded lower over the last trading session, losing -2.95% on 02/22/21. The shares fell to a low of $11.06 before closing at $11.19. BCRX’s previous close was $11.53 while the outstanding shares total 176.52M. The firm has a beta of 2.83.
Investors have identified the Biotechnology company BioCryst Pharmaceuticals Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $1.85 billion, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
BioCryst Pharmaceuticals Inc. (BCRX) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. For BCRX, the company has in raw cash 98.7 million on their books with 19.15 million currently as liabilities. How the trend is over time is what investors should be concerned about. The company has a healthy balance sheet as their debt profile has been on an incline. In terms of their assets, the company currently has 162.44 million total, with 111.78 million as their total liabilities.
Having a look at the company’s valuation, the company is expected to record -0.95 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on BCRX sounds very interesting.
Is the stock of BCRX attractive?
In related news, President & CEO, Stonehouse Jon P sold 134,278 shares of the company’s stock in a transaction that recorded on Dec 15. The sale was performed at an average price of 8.32, for a total value of 1,117,193. As the sale deal closes, the Senior VP, Chief Legal Officer, Barnes Alane P now sold 13,741 shares of the company’s stock, valued at 109,378. Also, Senior VP, Chief Legal Officer, Barnes Alane P sold 13,741 shares of the company’s stock in a deal that was recorded on Dec 04. The shares were price at an average price of 6.23 per share, with a total market value of 85,606. Following this completion of acquisition, the Chief Financial Officer, Doyle Anthony now holds 54,000 shares of the company’s stock, valued at 220,320. In the last 6 months, insiders have changed their ownership in shares of company stock by 0.60%.
8 out of 10 analysts covering the stock have rated it a Buy, while 2 have maintained a Hold recommendation on BioCryst Pharmaceuticals Inc.. 0 analysts has assigned a Sell rating on the BCRX stock. The 12-month mean consensus price target for the company’s shares has been set at $11.88.